Voyager Therapeutics, Inc.
HealthcareNASDAQ:VYGR · NASDAQ Global Select
+$0.04 today
Vol 0.54M · Avg 0.59M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.1%
avg -44.6%
ROIC
-56.4%
avg -26.4%
ROA
-47.5%
avg -19.3%
Analysis
ROA is currently the strongest return metric at -47.5% versus its period average of -19.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alfred W. Sandrock Jr. | President, Chief Executive Officer & Director | $1.05M | — | 68 | $472,549.00 | 0.78% |
Robin Swartz | Principal Financial Officer, Treasurer, Chief Business Officer & COO | $738,950.00 | — | 55 | $199,738.00 | 0.33% |
Nathan D. Jorgensen | Chief Financial Officer | $577,748.00 | — | 49 | $151,416.00 | 0.25% |
Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer | — | — | 49 | — | — |
Krystof Bankiewicz | Founder | — | — | — | — | — |
Mathieu Nonnenmacher | Vice President of Gene Therapy | — | — | — | — | — |
Mihalis Kariolis | Vice President of Non-Viral Therapeutics | — | — | — | — | — |
Gregory Shiferman | Senior VP, General Counsel & Secretary | — | — | 41 | $50,000.00 | 0.08% |
Todd Carter | Chief Scientific Officer | — | — | 56 | $145,718.00 | 0.24% |
Amy Quinlan | Principal Accounting Officer | — | — | 51 | $0.00 | <0.01% |
Mark A. Kay | Founder | — | — | 67 | $15,000.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
13
$405,470.24
Net Sentiment
$405,470.24
Net selling
Most Active
Sandrock Alfred
4 transactions
1–10 of 13
Analysis
Insiders reported 0 buys worth $0.00 and 13 sells worth $405,470.24 over the last 12 months. That adds up to net selling of $405,470.24. Sandrock Alfred was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +18.8% (13yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Forward estimates point to Revenue at +18.8% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Who manages VYGR?
Voyager Therapeutics, Inc. (VYGR) lists 11 active executives. The top listed executive is Nathan D. Jorgensen, Chief Financial Officer.
Are VYGR insiders buying or selling?
Recent insider activity shows net buying of $58.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.